|
|
Substance Name: Aclarubicin [USAN:INN:BAN]
RN: 57576-44-0
UNII: 74KXF8I502
InChIKey: USZYSDMBJDPRIF-SVEJIMAYSA-N
Note
- An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.
Molecular Formula
- C42-H53-N-O15
Molecular Weight
- 811.8727
Classification Codes
- Antibiotics, Antineoplastic
- Antineoplastic
- Antineoplastic Agents
- Drug / Therapeutic Agent
- Enzyme Inhibitors
- Mutation Data
- Natural Product
- Reproductive Effect
- Skin / Eye Irritant
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Aclacinomycin A
- Aclarubicin
- Aclarubicin [USAN:INN:BAN]
MeSH Heading
- Aclarubicin
Synonyms
- 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-
- Aclacinomycin A
- Aclacur
- Aclarubicin
- Aclarubicine
- Aclarubicine [INN-French]
- Aclarubicino
- Aclarubicino [INN-Spanish]
- Aclarubicinum
- Aclarubicinum [INN-Latin]
- Aclucinomycin A
- Antibiotic MA 144A
- Antibiotic MA 144A1
- CCRIS 2262
- EINECS 260-824-3
- MA 144-A1
- Methyl (1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-1-naphthacenecarboxylate
- NSC 208734
- NSC-208734
- UNII-74KXF8I502
Systematic Names
- 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-
- 1-Naphthacenecarboxylic acid,(2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-Lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-
- Aclacinomycin A
- Aclarubicin
Registry Numbers
CAS Registry Number
- 57576-44-0
FDA UNII
- 74KXF8I502
Other Registry Number
- 72711-48-9
System Generated Number
- 0057576440
Structure Descriptors
InChI
1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1InChIKey
USZYSDMBJDPRIF-SVEJIMAYSA-NSmiles
CC[C@@]1(O)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LDLo | intravenous | 5mg/kg (5mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: FOOD INTAKE (ANIMAL) | Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980. |
mammal (species unspecified) | LD50 | intraperitoneal | 25mg/kg (25mg/kg) | Antibiotiki. Vol. 29, Pg. 748, 1984. | |
mouse | LD50 | intraperitoneal | 16100ug/kg (16.1mg/kg) | Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985. | |
mouse | LD50 | intravenous | 16500ug/kg (16.5mg/kg) | Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985. | |
mouse | LD50 | oral | 30100ug/kg (30.1mg/kg) | Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985. | |
mouse | LD50 | subcutaneous | 22100ug/kg (22.1mg/kg) | Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985. | |
rat | LD50 | intraperitoneal | 17400ug/kg (17.4mg/kg) | BLOOD: CHANGES IN CELL COUNT (UNSPECIFIED) BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE | Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 32, Pg. 915, 1987. |
rat | LD50 | intravenous | 25710ug/kg (25.71mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980. |
rat | LD50 | oral | 58560ug/kg (58.56mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980. |
rat | LD50 | subcutaneous | 20mg/kg (20mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: FOOD INTAKE (ANIMAL) | Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980. |